QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
Open Access
- 26 October 2010
- Vol. 65 (12), 1086-1091
- https://doi.org/10.1136/thx.2010.139113
Abstract
Background This randomised, double-blind, placebo controlled, four-period crossover study assessed the efficacy and safety of once-daily QVA149, a dual bronchodilator consisting of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods Patients (N=154) were randomly assigned to receive QVA149 (indacaterol/NVA237) 300/50 μg, indacaterol 300 μg, indacaterol 600 μg, or placebo, once daily for 7 days with a 7-day washout period between each treatment. The primary endpoint was trough forced expiratory volume in 1 s (FEV1) (mean of 23 h 15 min and 23 h 45 min post-dose values) on day 7. Other endpoints included trough FEV1 on day 1, individual time point FEV1 and monitoring and recording of all adverse events. Results A total of 135 (87.7%) patients completed the study (all randomly assigned patients: mean age 61.7 years, 61.4% male, post-bronchodilator FEV1 52.2% predicted, FEV1/forced vital capacity 47.6%). The estimated treatment difference (95% CI) for trough FEV1 on day 7 between QVA149 and placebo was 226 ml (192 to 260; p1 exceeded the predefined minimal clinically important differences of 100–140 ml for QVA149 versus placebo and indacaterol. Similar results were observed on day 1. All treatments were well tolerated. Conclusions QVA149 demonstrated rapid and sustained bronchodilation with significant improvements compared with indacaterol monotherapy and placebo in patients with COPD. Clinical trial registration NCT00570778.This publication has 25 references indexed in Scilit:
- Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulmonary Pharmacology & Therapeutics, 2010
- Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPDThorax, 2010
- Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulmonary Medicine, 2010
- Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespiratory Medicine, 2009
- Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2009
- Outcomes for COPD pharmacological trials: from lung function to biomarkersEuropean Respiratory Journal, 2008
- Adherence to treatment by patients with asthma or COPD: Comparison between inhaled drugs and transdermal patchRespiratory Medicine, 2007
- Onset and Duration of Action of Formoterol and Tiotropium in Patients with Moderate to Severe COPDRespiration, 2006
- Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEuropean Respiratory Journal, 2005